Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia (Q40490614)

21 September 2017

1 reference

title

Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia (English)

1 reference

21 September 2017

D H Peters

1 reference

21 September 2017

E M Sorkin

series ordinal

1 reference

21 September 2017

publication date

1 July 1993

1 reference

21 September 2017

1 reference

21 September 2017

1 reference

21 September 2017

1 reference

21 September 2017

page(s)

177-208

1 reference

High-performance liquid chromatographic determination of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a 4-azasteroid, in human plasma from a phase I study

21 September 2017

cites work

1 reference

12 December 2020

Effect of Finasteride, a 5α-Reductase Inhibitor on Prostate Tissue Androgens and Prostate-Specific Antigen*

1 reference

12 December 2020

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia

1 reference

12 December 2020

Pathogenesis of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Validation of a symptoms questionnaire for benign prostatic hyperplasia

1 reference

12 December 2020

The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

1 reference

12 December 2020

The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Natural history of benign prostatic hypertrophy and acute urinary retention

1 reference

12 December 2020

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders

1 reference

12 December 2020

Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions

1 reference

12 December 2020

Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Pathogenesis and medical treatment of benign prostatic hyperplasia

1 reference

12 December 2020

5 Alpha-reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat

1 reference

12 December 2020

Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans

1 reference

12 December 2020

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, i

1 reference

12 December 2020

High-performance liquid chromatographic method for the determination of finasteride in human plasma at therapeutic doses

1 reference

12 December 2020

Androgen ablation and blockade in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

1 reference

12 December 2020

Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans

1 reference

12 December 2020

Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia

1 reference

12 December 2020

The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia

1 reference

12 December 2020

Molecular genetics of steroid 5 alpha-reductase 2 deficiency

1 reference

12 December 2020

Species differences in prostatic steroid 5 alpha-reductases of rat, dog, and human

1 reference

12 December 2020

Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia

1 reference

12 December 2020

The steroid 5 -reductase activity of rat liver and prostate

1 reference

12 December 2020

Sexual differentiation of the central nervous system

1 reference

12 December 2020

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

1 reference

12 December 2020

Urodynamic and histological correlates of benign prostatic hyperplasia

1 reference

12 December 2020

Effects of Flutamide and Finasteride on Rat Testicular Descent

1 reference

12 December 2020

Surgical management for benign prostatic hyperplasia: indications, techniques, and results

1 reference

12 December 2020

Nonoperative management of benign prostatic hyperplasia

1 reference

12 December 2020

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers

1 reference

12 December 2020

Symptom status and quality of life following prostatectomy.

1 reference

12 December 2020

Inhibition of testosterone conversion to dihydrotestosterone in men treated percutaneously by progesterone

1 reference

12 December 2020

Testosterone: a major determinant of extragenital sexual dimorphism

1 reference

12 December 2020

Copulation in Castrated Male Rats following Combined Treatment with Estradiol and Dihydrotestosterone

1 reference

12 December 2020

Natural history of benign prostatic hyperplasia (BPH)

1 reference

12 December 2020

Critical evaluation of transurethral resection and incision of the prostate

1 reference

12 December 2020

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

1 reference

12 December 2020

Watchful waiting vs immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences

1 reference

12 December 2020

Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men

1 reference

12 December 2020

BPH epidemiology and risk factors

1 reference

12 December 2020

The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy

1 reference

12 December 2020

External genitalia abnormalities in male rats exposed in utero to finasteride, a 5 alpha-reductase inhibitor.

1 reference

12 December 2020

The development of human benign prostatic hyperplasia with age

1 reference

12 December 2020

Medical management of benign prostatic hyperplasia with androgen suppression

1 reference

12 December 2020

Anatomy of the prostate and morphogenesis of BPH

1 reference

12 December 2020

Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy.

1 reference

12 December 2020

4-Azasteroidal 5 alpha-reductase inhibitors without affinity for the androgen receptor

1 reference

12 December 2020

Clinical experience: symptomatic management of BPH with terazosin

1 reference

12 December 2020

Magnetic resonance imaging of the efficacy of specific inhibition of 5α-reductase in canine spontaneous benign prostatic hyperplasia

1 reference

12 December 2020

Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase

1 reference

12 December 2020

Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism

1 reference

12 December 2020

One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group

1 reference

12 December 2020

Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men

1 reference

12 December 2020

Differential Effect of 5α-Reductase Inhibition and Castration on Androgen-Regulated Gene Expression in Rat Prostate

1 reference

12 December 2020

Alpha-adrenoceptor inhibitors in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

1 reference

12 December 2020

Mechanism of thyroxine-induced increase in steroid delta4-reductase activity in male rats

1 reference

12 December 2020

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

1 reference

12 December 2020

The effect of finasteride on prostate‐specific antigen in men with benign prostatic hyperplasia

1 reference

12 December 2020

Diagnostic assessment of benign prostatic hyperplasia

1 reference

12 December 2020

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

1 reference

12 December 2020

Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors

1 reference

12 December 2020

Origin and evolution of benign prostatic enlargement

1 reference

12 December 2020

The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat

1 reference

12 December 2020

Effects of androgenic and oestrogenic hormones on mating behaviour in rams castrated before and after puberty

1 reference

12 December 2020

Natural history of benign prostatic hypertrophy

1 reference

12 December 2020

Finasteride for benign prostatic hyperplasia

1 reference

12 December 2020

Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency

1 reference

12 December 2020

Etiology and disease process of benign prostatic hyperplasia

1 reference

12 December 2020

Medical and nonmedical therapies for benign prostatic hypertrophy

1 reference

12 December 2020

C19and C215β/5αMetabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency*

1 reference

12 December 2020

Sex steroids in the umbilical circulation of fetal rhesus monkeys from the time of gonadal differentiation

1 reference

12 December 2020

The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism

1 reference

12 December 2020

Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding

1 reference

12 December 2020

Review of current and future approaches to the management of benign prostatic hyperplasia

1 reference

12 December 2020

Sexual differentiation: early hormone synthesis and action

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Selective Retention of Dihydrotestosterone by Prostatic Nuclei

1 reference

12 December 2020

Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide

1 reference

12 December 2020

A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy

1 reference

12 December 2020

Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5α-reductase inhibitor

1 reference

12 December 2020

10.2165/00003495-199346010-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

21 September 2017

1000171507

0 references

1 reference